ARBs cut risk of CVD events in hypertension
Adding an angiotensin receptor blocker (ARB) to the treatment of patients with uncontrolled blood pressure reduces the risk of cardiovascular complications, a new trial has found.
The trial, of 3031 patients from Japan, found that adding valsartan reduced the risk of cardiovascular events by 45%, compared to non-ARB, non-ACE inhibitor treatment that lowered blood pressure by the same amount. The number of patients who needed to take valsartan to prevent a cardiovascular complication was 21.
But the Kyoto heart study found that the main difference between the treatments was a reduction in cases of angina and strokes over the four years of follow up. There was no significant difference in the numbers of heart attacks or in the development of heart failure. There was also no significant reduction in cardiovascular death or all-cause mortality.